🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🧬Could IL-6 signaling be the true therapeutic target behind the smokescreen of hs-CRP? 👉While hs-CRP has long been used as a biomarker of residual inflammatory risk, human genetics suggests it may not be the driver we once thought 👉The IL-6 signaling pathway has emerged as a

A few thoughts on Herasight, the new embryo selection company. First, the post below and the white paper imply that competitors like Nucleus have been marketing and selling grossly erroneous risk estimates. This is shocking if true! 🧵

Is there any serious reason to include IQ in the first set of traits this embyo selection startup provides predictions for? Meanwhile, so many medically relevant traits are left out, e.g. coronary artery disease, stroke, LDL, BMI. Feels hype-chasing.